Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.

Pombo Antunes AR, Scheyltjens I, Duerinck J, Neyns B, Movahedi K, Van Ginderachter JA.

Elife. 2020 Feb 4;9. pii: e52176. doi: 10.7554/eLife.52176.

2.

Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study.

Rogiers A, Leys C, De Cremer J, Awada G, Schembri A, Theuns P, De Ridder M, Neyns B.

Support Care Cancer. 2019 Nov 19. doi: 10.1007/s00520-019-05168-3. [Epub ahead of print]

PMID:
31745697
3.

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.

Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, Awada G, Schwarze JK, Keyaerts M, Everaert H, Lienard D, Del Marmol V, Heimann P, Neyns B.

J Transl Med. 2019 Sep 5;17(1):303. doi: 10.1186/s12967-019-2051-8.

4.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV.

Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.

PMID:
31345627
5.

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.

de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV.

Eur J Endocrinol. 2019 Sep;181(3):363-374. doi: 10.1530/EJE-19-0291.

6.

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B.

J Oncol. 2019 Apr 28;2019:5269062. doi: 10.1155/2019/5269062. eCollection 2019. Review.

7.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.

Martin-Algarra S, Hinshelwood R, Mesnage S, Cebon J, Ferrucci PF, Aglietta M, Neyns B, Chiarion-Sileni V, Lindsay CR, Del Vecchio M, Linardou H, Merelli B, Tonini G, Atkinson V, Freivogel K, Stein D, Dalland L, Lau M, Legenne P, Queirolo P, Millward M.

Melanoma Res. 2019 Oct;29(5):527-532. doi: 10.1097/CMR.0000000000000608.

PMID:
31095039
8.

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.

Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, Teijeira A, Kandalaft LE, Romero P, Coukos G, Neyns B, Sancho D, Melero I, de Vries IJM.

J Immunother Cancer. 2019 Apr 18;7(1):109. doi: 10.1186/s40425-019-0580-6. Review.

9.

Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases.

Jansen YJL, Verset G, Schats K, Van Dam PJ, Seremet T, Kockx M, Van Laethem JB, Neyns B.

ESMO Open. 2019 Mar 5;4(2):e000464. doi: 10.1136/esmoopen-2018-000464. eCollection 2019.

10.

Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.

Sundahl N, Seremet T, Van Dorpe J, Neyns B, Ferdinande L, Meireson A, Brochez L, Kruse V, Ost P.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):828-835. doi: 10.1016/j.ijrobp.2019.03.041. Epub 2019 Apr 3.

PMID:
30951807
11.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B.

Ann Oncol. 2019 Jul 1;30(7):1154-1161. doi: 10.1093/annonc/mdz110.

PMID:
30923820
12.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C.

Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20.

PMID:
30580112
13.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C.

Eur J Cancer. 2018 Nov;104:201-209. doi: 10.1016/j.ejca.2018.09.013. Epub 2018 Oct 31.

PMID:
30388700
14.

Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test.

Seremet T, Haccuria A, Lienard D, Del Marmol V, Neyns B.

Melanoma Res. 2019 Feb;29(1):95-98. doi: 10.1097/CMR.0000000000000529.

PMID:
30383722
15.

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.

Seremet T, Planken S, Schwarze JK, Jansen Y, Vandeweerd L, van den Begin R, Tsechelidis I, Lienard D, Del Marmol V, Neyns B.

Melanoma Res. 2019 Feb;29(1):85-88. doi: 10.1097/CMR.0000000000000501.

PMID:
30211812
16.

Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition.

Awada G, Seremet T, Fostier K, Everaert H, Neyns B.

Blood Adv. 2018 Aug 28;2(16):2156-2158. doi: 10.1182/bloodadvances.2018021782. No abstract available.

17.

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab.

Du Four S, Janssen Y, Michotte A, Van Binst AM, Van den Begin R, Duerinck J, Neyns B.

Cancer Med. 2018 Oct;7(10):4870-4879. doi: 10.1002/cam4.1726. Epub 2018 Aug 21.

18.

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.

Baurain JF, Robert C, Mortier L, Neyns B, Grange F, Lebbe C, Ulloa-Montoya F, De Sousa Alves PM, Gillet M, Louahed J, Jarnjak S, Lehmann FF.

ESMO Open. 2018 Jul 25;3(5):e000384. doi: 10.1136/esmoopen-2018-000384. eCollection 2018.

19.

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.

Schats KA, Van Vré EA, Boeckx C, De Bie M, Schrijvers DM, Neyns B, De Meester I, Kockx MM.

Arch Pathol Lab Med. 2018 Aug;142(8):982-991. doi: 10.5858/arpa.2017-0159-OA. Epub 2018 Apr 2.

PMID:
29607663
20.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

21.

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.

Seremet T, Planken S, Schreuer M, Jansen Y, Delaunoy M, El Housni H, Lienard D, Del Marmol V, Heimann P, Neyns B.

Melanoma Res. 2018 Feb;28(1):65-70. doi: 10.1097/CMR.0000000000000415.

PMID:
29227333
22.

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.

Grob JJ, Mortier L, D'Hondt L, Grange F, Baurain JF, Dréno B, Lebbe C, Robert C, Dompmartin A, Neyns B, Gillet M, Louahed J, Jarnjak S, Lehmann FF.

ESMO Open. 2017 Nov 14;2(5):e000203. doi: 10.1136/esmoopen-2017-000203. eCollection 2017.

23.

Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.

Duerinck J, Du Four S, Bouttens F, Andre C, Verschaeve V, Van Fraeyenhove F, Chaskis C, D'Haene N, Le Mercier M, Rogiers A, Michotte A, Salmon I, Neyns B.

J Neurooncol. 2018 Jan;136(1):115-125. doi: 10.1007/s11060-017-2629-z. Epub 2017 Oct 7.

PMID:
28988341
24.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C.

Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16.

PMID:
28822576
25.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J.

J Clin Oncol. 2018 Feb 1;36(4):383-390. doi: 10.1200/JCO.2016.71.8023. Epub 2017 Jul 3.

26.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP.

Eur J Cancer. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.

PMID:
28501764
27.

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, Neyns B.

Lancet Oncol. 2017 Apr;18(4):464-472. doi: 10.1016/S1470-2045(17)30171-7. Epub 2017 Mar 4.

PMID:
28268064
28.

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C.

Eur J Cancer. 2017 Apr;75:313-322. doi: 10.1016/j.ejca.2017.01.012. Epub 2017 Mar 4.

PMID:
28264791
29.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH Jr, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD.

J Clin Oncol. 2017 Jan 10;35(2):226-235. Epub 2016 Nov 7.

30.

Population Pharmacokinetic Approach Applied to Positron Emission Tomography: Computed Tomography for Tumor Tissue Identification in Patients with Glioma.

Gandia P, Jaudet C, Everaert H, Heemskerk J, Vanbinst AM, de Mey J, Duerinck J, Neyns B, de Ridder M, Chatelut E, Concordet D.

Clin Pharmacokinet. 2017 Aug;56(8):953-961. doi: 10.1007/s40262-016-0490-4.

PMID:
27995528
31.

Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.

Du Four S, Maenhout SK, Niclou SP, Thielemans K, Neyns B, Aerts JL.

Am J Cancer Res. 2016 Nov 1;6(11):2514-2531. eCollection 2016.

32.

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.

de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B.

J Clin Endocrinol Metab. 2016 Nov;101(11):4431-4439. Epub 2016 Aug 29.

33.

Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.

Schats KA, Van Vré EA, De Schepper S, Boeckx C, Schrijvers DM, Waelput W, Fransen E, Vanden Bempt I, Neyns B, De Meester I, Kockx MM.

Histopathology. 2017 Jan;70(2):253-263. doi: 10.1111/his.13056. Epub 2016 Oct 10.

PMID:
27496355
34.

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.

Seremet T, Koch A, Jansen Y, Schreuer M, Wilgenhof S, Del Marmol V, Liènard D, Thielemans K, Schats K, Kockx M, Van Criekinge W, Coulie PG, De Meyer T, van Baren N, Neyns B.

J Transl Med. 2016 Aug 2;14(1):232. doi: 10.1186/s12967-016-0990-x.

35.

Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report.

Demeulenaere M, Duerinck J, DU Four S, Fostier K, Michotte A, Neyns B.

Anticancer Res. 2016 Aug;36(8):4145-9.

PMID:
27466523
36.

Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.

Du Four S, Maenhout SK, Benteyn D, De Keersmaecker B, Duerinck J, Thielemans K, Neyns B, Aerts JL.

Cancer Immunol Immunother. 2016 Jun;65(6):727-40. doi: 10.1007/s00262-016-1836-3. Epub 2016 Apr 20.

PMID:
27098427
37.

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.

Schreuer M, Meersseman G, Van Den Herrewegen S, Jansen Y, Chevolet I, Bott A, Wilgenhof S, Seremet T, Jacobs B, Buyl R, Maertens G, Neyns B.

J Transl Med. 2016 Apr 19;14:95. doi: 10.1186/s12967-016-0852-6.

38.

Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.

Duerinck J, Du Four S, Vandervorst F, D'Haene N, Le Mercier M, Michotte A, Van Binst AM, Everaert H, Salmon I, Bouttens F, Verschaeve V, Neyns B.

J Neurooncol. 2016 May;128(1):147-155. doi: 10.1007/s11060-016-2092-2. Epub 2016 Mar 2.

PMID:
26935577
39.

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.

Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, Thielemans K, Neyns B.

J Clin Oncol. 2016 Apr 20;34(12):1330-8. doi: 10.1200/JCO.2015.63.4121. Epub 2016 Feb 29.

PMID:
26926680
40.

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.

Decoster L, Vande Broek I, Neyns B, Majois F, Baurain JF, Rottey S, Rorive A, Anckaert E, De Mey J, De Brakeleer S, De Grève J.

Anticancer Res. 2015 Dec;35(12):6893-9.

PMID:
26637913
41.

Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma.

Schreuer M, Meersseman G, van Den Herrewegen S, Jansen Y, Seremet T, Bott A, Chevolet I, Wilgenhof S, Maertens G, Neyns B.

Melanoma Res. 2016 Apr;26(2):157-63. doi: 10.1097/CMR.0000000000000224.

PMID:
26636909
42.

Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.

Jansen YJ, Janssens P, Hoorens A, Schreuer MS, Seremet T, Wilgenhof S, Neyns B.

Melanoma Res. 2015 Dec;25(6):550-4. doi: 10.1097/CMR.0000000000000186.

PMID:
26512791
43.

Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.

Duerinck J, Du Four S, Sander W, Van Binst AM, Everaert H, Michotte A, Hau P, Neyns B.

Anticancer Res. 2015 Oct;35(10):5551-7.

PMID:
26408725
44.

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.

Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Mus RD, Croockewit SA, Jacobs JF, Schuler G, Neyns B, Austyn JM, Punt CJ, Schreibelt G, de Vries IJ.

Oncoimmunology. 2015 Apr 1;4(8):e1019197. eCollection 2015 Aug.

45.

Vemurafenib-associated Dupuytren- and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients.

Vandersleyen V, Grosber M, Wilgenhof S, De Kock J, Neyns B, Gutermuth J.

J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1133-5. doi: 10.1111/jdv.13268. Epub 2015 Aug 24.

PMID:
26303964
46.

Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.

Du Four S, Maenhout SK, De Pierre K, Renmans D, Niclou SP, Thielemans K, Neyns B, Aerts JL.

Oncoimmunology. 2015 Jan 22;4(4):e998107. eCollection 2015 Apr.

48.

Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?

Chevolet I, Schreuer M, Speeckaert R, Neyns B, Hoorens I, van Geel N, Krüse V, Hennart B, Allorge D, Van Gele M, Brochez L.

Melanoma Res. 2015 Aug;25(4):357-61. doi: 10.1097/CMR.0000000000000171.

PMID:
26050145
49.

Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.

Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, Van Gele M, Brochez L.

Oncoimmunology. 2015 Apr 2;4(3):e982382. eCollection 2015 Mar.

50.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators.

N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.

Supplemental Content

Support Center